FAQ

NovoTTF-100A Device

Known as: NovoTumor Treatment Fields, NovoTTFields, Optune Device 
A portable, battery-operated device that is used to apply low intensity, alternating electric fields, also called tumor treatment fields (TTFs… (More)

Topic mentions per year

Topic mentions per year

2008-2018
012320082018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.
BACKGROUND Gangliogliomas are slow-growing, low-grade central nervous system tumors affecting children and young adults. However… (More)
Is this relevant?
2015
2015
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation
The NovoTTF-100A is a device that emits alternating electric fields and it is approved for the treatment of recurrent… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma
The NovoTTF-100A device emits frequency-tuned alternating electric fields that interfere with tumor cell mitosis. In phase III… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.
The NovoTTF-100A System (NovoTTF™ Therapy, Novocure Inc.) is a device that delivers alternating electric fields (TTFields) to… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2014
2014
Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100Aâ„¢ system versus best physician's choice chemotherapy.
We performed a treatment-based analysis of data from the pivotal phase III trial of the NovoTTF-100A System™ versus best… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2013
2013
Delayed response and survival from NovoTTF-100A in recurrent GBM.
We present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the NovoTTF-100A landmark phase III study and… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
PURPOSE NovoTTF-100A is a portable device delivering low-intensity, intermediate frequency electric fields via non-invasive… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2012
Review
2012
NovoTTF-100A: a new treatment modality for recurrent glioblastoma.
NovoTTF-100A (Novocure Inc., Haifa, Israel) is a first-of-a-kind device approved by the US FDA for the treatment of recurrent… (More)
Is this relevant?
2010
2010
A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma.
LBA2007 Background: The NovoTTF is a portable, medical device delivering low intensity, intermediate frequency, alternating… (More)
Is this relevant?
2008
2008
A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors.
BACKGROUND The transmission of electric fields using insulated electrodes has demonstrated that very low-intensity, properly… (More)
Is this relevant?